Source comparison
GHRP-2 Acetate vs Tesamorelin: Side Effect Profiles and Safety Considerations
Tesamorelin's most common adverse events in clinical trials were injection site reactions (erythema, pruritus) occurring in 26% of patients, typically resolving within 48–72 hours. Serious adverse events occurred at rates comparable to placebo, with no cases o
This comparison does not assign a generated winner or score.
- Tesamorelin's most common adverse events in clinical trials were injection site reactions (erythema, pruritus) occurring in 26% of patients, typically resolving within 48–72 hours. Serious adverse events occurred at rates comparable to placebo, with no cases of tesamorelin-induced diabetes despite sustained IGF-1 elevation. The peptide's selective GHRH agonism avoids ghrelin pathway effects. No appetite stimulation, no cortisol spikes, no prolactin elevation. Contraindications include active malignancy (GH can promote tumour growth in existing cancers) and disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, or pituitary tumour. Patients with glucose intolerance should be monitored closely, as GH's anti-insulin effects can unmask latent hyperglycaemia in predisposed individuals.
- GHRP-2 acetate's side effect profile reflects its ghrelin receptor activity. Transient cortisol elevation (20–40% above baseline) peaks 60–90 minutes post-injection and normalises within 3–4 hours, but repeated daily administration can theoretically stress the adrenal axis over months. Prolactin increases are modest (typically within physiological range) but may accumulate with chronic use. Water retention occurs in approximately 15–20% of research subjects at doses above 100mcg, attributable to GH-mediated sodium retention and extracellular fluid expansion. Hunger stimulation is dose-dependent. 50mcg typically produces minimal appetite changes, while 200mcg can provoke noticeable feeding behaviour within 30–60 minutes post-injection. Joint discomfort (arthralgia) and carpal tunnel symptoms can emerge with supraphysiological GH levels sustained over weeks, resolving upon dose reduction or cessation.
- Neither peptide demonstrates hepatotoxicity or nephrotoxicity in clinical studies. Both require refrigeration at 2–8°C post-reconstitution and retain potency for 28 days when stored properly. Lyophilised powder should be stored at −20°C before mixing with bacteriostatic water. A critical distinction: tesamorelin's longer half-life (approximately 38 minutes versus GHRP-2's 20 minutes) allows once-daily dosing, while GHRP-2's shorter duration typically requires twice- or thrice-daily administration to maintain elevated GH throughout the day.